Zhiming Hao

Tofacitinib therapy improves disease activity and is associated with the restoration of CD4+ regulatory T cell homeostasis in active Takayasu arteritis: a two-year prospective open-label cohort study

To investigate the efficacy of Tofacitinib (TOF) in patients with active Takayasu Arteritis (TAK), and to explore its effect on CD4 + regulatory T cells (Tregs) homeostasis and its relationship with clinical outcomes. This was a prospective, open-label cohort study. Thirty-four p...